- The key vendors in the Epilepsy Market in the US 2015-2019 are GlaxoSmithKline plc, Pfizer Inc. and UCB SA.
London, 31 December 2014: TechNavio, an independent tech-focused global research firm, has announced the publication of its market research report on the Epilepsy Market in the US 2015-2019. One key trend emerging in this market is the reformulation of marketed drugs. Reformulated drugs have better tolerability and better dosing schedules than the original drugs. This increases the market acceptance of such drugs, driving the growth of the market. The market in the US is expected to post a CAGR of 4.85 percent during the period 2014-2019.
Epilepsy refers to a spectrum of brain disorders manifested by benign to severe, disabling, and life-threatening symptoms. It is caused by factors ranging from brain malformations and tumors to meningitis, high-risk pregnancies, and trauma during birth.
“Several global and national-level campaigns are being conducted to increase awareness about epilepsy,” says Faisal Ghaus, Vice President of TechNavio Research.
“For example, the CDC runs the MEW network to improve the quality of care provided to epileptic patients. MEW works through various programs such as WebEase, UPLIFT, and PEARLS.”
To define the market conditions in the next 3-4 years, TechNavio analysts have conducted in-depth analysis of the impact of market drivers, challenges and trends featuring data on product segmentations, vendor shares, growth rate by revenue and an evaluation of the different buying criteria in the order of importance.
https://www.technavio.com/%3Cp%3EIf%20you%20are%20interested%20in%20more%…
